Aliases & Classifications for Dengue Hemorrhagic Fever

MalaCards integrated aliases for Dengue Hemorrhagic Fever:

Name: Dengue Hemorrhagic Fever 38 12 55 3 15
Severe Dengue 44 73
Dhf 12 3
Dengue Haemorrhagic Fever 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12206
ICD10 33 A91
MeSH 44 D019595
NCIt 50 C34683
UMLS 73 C0019100

Summaries for Dengue Hemorrhagic Fever

Disease Ontology : 12 A dengue disease that occurs when a person experiences a second infection with a heterologous Dengue virus serotype, which is transmitted by Aedes mosquito bite. The infection has symptom hemorrhagic lesions of the skin, has symptom thrombocytopenia, has symptom reduction in the fluid part of the blood, and has symptom high fever.

MalaCards based summary : Dengue Hemorrhagic Fever, also known as severe dengue, is related to compartment syndrome and japanese encephalitis, and has symptoms including hemorrhagic lesions of the skin, thrombocytopenia and reduction in the fluid part of the blood. An important gene associated with Dengue Hemorrhagic Fever is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include skin, endothelial and kidney, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

CDC : 3 Get Email Updates

Related Diseases for Dengue Hemorrhagic Fever

Diseases related to Dengue Hemorrhagic Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 396)
# Related Disease Score Top Affiliating Genes
1 compartment syndrome 30.8 ALB F2 TNF
2 japanese encephalitis 30.8 CD209 STAT1 TNF
3 hantavirus pulmonary syndrome 30.3 CD40LG F2 F3
4 myocarditis 30.1 CD40LG IL6 TNF
5 hemophagocytic lymphohistiocytosis 30.1 CXCL8 IFNG IL10 TNF
6 acute pancreatitis 30.0 CXCL8 IL10 IL6
7 dengue shock syndrome 29.9 CMA1 HLA-A IL6 TNF
8 purpura 29.8 CD40LG F2 F3 TNF
9 acute respiratory distress syndrome 29.7 CXCL8 IL6 TNF
10 gingivitis 29.7 CXCL8 IL6 TNF
11 kawasaki disease 29.4 ALB FCGR2A IL10 IL6 TNF
12 filariasis 29.3 ALB IFNG IL10 IL6 TNF
13 typhoid fever 29.3 ALB F2 IFNG IL6 TNF
14 hepatitis a 29.2 ALB CD40LG F2 F3 TNF
15 hemorrhagic fever 28.6 ALB CD209 CD40LG F2 F3 HLA-DRB1
16 pneumonia 28.5 CD40LG CXCL8 IL10 IL6 TNF
17 acquired immunodeficiency syndrome 28.4 ALB CD40LG IFNG IL10 IL6 TNF
18 peritonitis 28.4 ALB CXCL8 F2 IL10 IL6 TNF
19 malaria 25.4 ALB CD40LG CXCL8 F3 FCGR2A HLA-A
20 dengue disease 12.1
21 dengue virus 11.6
22 punctate inner choroidopathy 11.0 IL10 TNF
23 tropical endomyocardial fibrosis 11.0 IL10 TNF
24 juvenile myasthenia gravis 10.9 HLA-DRB1 IL10
25 multifocal choroiditis 10.9 IL10 TNF
26 endomyocardial fibrosis 10.8 IL10 TNF
27 cerebral falx meningioma 10.8 F2 F3
28 antipyrine metabolism 10.8 ALB F2
29 non-a-e hepatitis 10.8 ALB F2
30 postherpetic neuralgia 10.8 HLA-A HLA-DRB1
31 hyperlucent lung 10.8 IFNG IL10
32 marburg hemorrhagic fever 10.8 CD209 F2 TNF
33 transient hypogammaglobulinemia 10.8 IL10 TNF
34 staphylococcal toxic shock syndrome 10.8 IFNG TNF
35 intestinal impaction 10.8 F2 F3
36 microscopic polyangiitis 10.8 HLA-DRB1 IL10 TNF
37 autoimmune myocarditis 10.8 IFNG TNF
38 cerebral sinovenous thrombosis 10.7 F2 F3
39 beryllium disease 10.7 HLA-DRB1 TNF
40 scorpion envenomation 10.7 IL6 TNF
41 orofacial granulomatosis 10.7 IFNG IL10 TNF
42 berylliosis 10.7 HLA-DRB1 IFNG
43 lepromatous leprosy 10.7 IFNG IL10 TNF
44 chronic beryllium disease 10.7 HLA-DRB1 IFNG TNF
45 leukomalacia 10.6 IL6 TNF
46 acute graft versus host disease 10.6 IFNG IL10 TNF
47 peanut allergy 10.6 HLA-DRB1 IFNG IL10
48 intracranial hypertension 10.6 F2 F3 TNF
49 angioimmunoblastic lymphadenopathy with dysproteinemia 10.6 IL6 TNF
50 tick-borne encephalitis 10.6 ALB CD209 IL10

Graphical network of the top 20 diseases related to Dengue Hemorrhagic Fever:



Diseases related to Dengue Hemorrhagic Fever

Symptoms & Phenotypes for Dengue Hemorrhagic Fever

Symptoms:

12
  • hemorrhagic lesions of the skin
  • thrombocytopenia
  • reduction in the fluid part of the blood
  • high fever

GenomeRNAi Phenotypes related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CD40LG CXCL8 F2 IL10 STAT1 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 CD40LG CXCL8 F2 IL10 STAT1 TNF

MGI Mouse Phenotypes related to Dengue Hemorrhagic Fever:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.14 STAT2 TNF IFNG CD40LG IL10 CMA1
2 immune system MP:0005387 10.11 STAT2 TNF IFNG CD40LG IL10 CMA1
3 mortality/aging MP:0010768 10 STAT1 STAT2 TNF FCGR2A ALB IFNG
4 digestive/alimentary MP:0005381 9.98 TNF STAT1 ALB IFNG IL10 F2
5 integument MP:0010771 9.92 TNF STAT1 IFNG CD40LG IL10 F2
6 muscle MP:0005369 9.7 TNF STAT1 ALB IFNG IL10 IL6
7 neoplasm MP:0002006 9.5 TNF ALB IFNG IL10 IL6 F3
8 skeleton MP:0005390 9.23 TNF STAT1 IFNG CD40LG IL10 F2

Drugs & Therapeutics for Dengue Hemorrhagic Fever

Drugs for Dengue Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
2
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
3 Anti-Allergic Agents Phase 4
4 Antipruritics Phase 4
5 Dermatologic Agents Phase 4
6 Histamine Antagonists Phase 4
7 Histamine H1 Antagonists Phase 4
8
Histamine Phosphate Phase 4 51-74-1 65513
9 Neurotransmitter Agents Phase 4
10
Ivermectin Approved, Investigational, Vet_approved Phase 2, Phase 3 70288-86-7 6474909
11 Pharmaceutical Solutions Phase 3,Phase 2
12 Anti-Infective Agents Phase 2, Phase 3
13 Antiparasitic Agents Phase 2, Phase 3
14 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable
15 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
16
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
17
Ribavirin Approved Phase 2 36791-04-5 37542
18
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
19 Antimetabolites Phase 2
20 Antiviral Agents Phase 2
21 Cortisol succinate Phase 2
22 Hydrocortisone 17-butyrate 21-propionate Phase 2
23 Hydrocortisone acetate Phase 2
24 Coagulants Phase 2
25 Hemostatics Phase 2
26 Antibodies Phase 1, Phase 2,Phase 2
27 Immunoglobulins Phase 1, Phase 2,Phase 2
28
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
29
Aluminum sulfate Approved Phase 1 10043-01-3
30 Adjuvants, Immunologic Phase 1
31 Antacids Phase 1
32 Anti-Ulcer Agents Phase 1
33 Gastrointestinal Agents Phase 1
34
Permethrin Approved, Investigational Not Applicable 52645-53-1 40326
35 gamma-Globulins Not Applicable
36 Immunoglobulins, Intravenous Not Applicable
37 Rho(D) Immune Globulin Not Applicable
38 Endothelial Growth Factors
39 Mitogens

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
3 Efficacy and Safety of Ivermectin Against Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
4 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Unknown status NCT01373281 Phase 3
5 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Unknown status NCT01374516 Phase 3
6 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
7 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
8 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
9 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
10 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Active, not recruiting NCT02992418 Phase 3
11 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
12 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Active, not recruiting NCT02979535 Phase 3
13 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Active, not recruiting NCT02747927 Phase 3 TDV Placebo
14 Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue Active, not recruiting NCT03423173 Phase 3
15 Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
16 Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever Completed NCT01601613 Phase 2 activated recombinant human factor VII;placebo
17 Celgosivir as a Treatment Against Dengue Completed NCT01619969 Phase 1, Phase 2 celgosivir;placebo
18 A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
19 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
20 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
21 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
22 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
23 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
24 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
25 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
26 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
27 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
28 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
29 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
30 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
31 A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children Completed NCT00468858 Phase 2
32 Safety and Immunogenicity With Two Different Serotype 2 Potencies of Tetravalent Dengue Vaccine (TDV) in Adults in Singapore Completed NCT02425098 Phase 2
33 Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Completed NCT02193087 Phase 2 TDV Liquid Formulation 1;TDV Liquid Formulation 2;TDV IDT Lyophilized;Placebo
34 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
35 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
36 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years Completed NCT01511250 Phase 2
37 VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Recruiting NCT03110770 Phase 2
38 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule Active, not recruiting NCT02824198 Phase 2
39 Immunogenicity and Safety of 3-Dose and Booster Dose of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age Active, not recruiting NCT02628444 Phase 2
40 Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule Active, not recruiting NCT02623725 Phase 2
41 Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants Active, not recruiting NCT02302066 Phase 2 TDV Placebo
42 Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Not yet recruiting NCT02569827 Phase 1, Phase 2 Celgosivir;Modipafant 50mg;Placebo;Modipafant 100mg
43 Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Not yet recruiting NCT03432442 Phase 2 Ivermectin
44 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Not yet recruiting NCT02741128 Phase 2
45 Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus Completed NCT00458120 Phase 1
46 A Study of Balapiravir in Patients With Dengue Virus Infection Completed NCT01096576 Phase 1 balapiravir [RO4588161];placebo
47 Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever Completed NCT01224639 Phase 1
48 Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus Completed NCT00919178 Phase 1
49 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults Completed NCT00831012 Phase 1
50 Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease Completed NCT01502735 Phase 1

Search NIH Clinical Center for Dengue Hemorrhagic Fever

Cochrane evidence based reviews: severe dengue

Genetic Tests for Dengue Hemorrhagic Fever

Anatomical Context for Dengue Hemorrhagic Fever

MalaCards organs/tissues related to Dengue Hemorrhagic Fever:

41
Skin, Endothelial, Kidney, Testes, Monocytes, Pituitary, Thyroid

Publications for Dengue Hemorrhagic Fever

Articles related to Dengue Hemorrhagic Fever:

(show top 50) (show all 516)
# Title Authors Year
1
Platelet Count, D-Dimer, Component Therapy and Dengue Hemorrhagic Fever. ( 29622891 )
2018
2
Climate variability and dengue hemorrhagic fever in Southeast Sulawesi Province, Indonesia. ( 29549613 )
2018
3
Dengue Hemorrhagic Fever Virus in Saudi Arabia: A Review. ( 29319426 )
2018
4
Prospective forecasts of annual dengue hemorrhagic fever incidence in Thailand, 2010-2014. ( 29463757 )
2018
5
The Autoimmune Mechanism in Dengue Hemorrhagic Fever. ( 29686179 )
2018
6
Culture-positive unilateral panophthalmitis in a serology-positive case of dengue hemorrhagic fever. ( 29941760 )
2018
7
Concurrent methicillin-resistant Staphylococcus aureus septicemia and pyomyositis in a patient with dengue hemorrhagic fever: a case report. ( 29486726 )
2018
8
Dengue hemorrhagic fever complicated with transient diabetic ketoacidosis: a case report. ( 29078811 )
2017
9
Vitamin D serostatus and dengue fever progression to dengue hemorrhagic fever/dengue shock syndrome. ( 28903788 )
2017
10
Association of Single-Nucleotide Polymorphisms in Immune-Related Genes with Development of Dengue Hemorrhagic Fever in a Mexican Population. ( 29130827 )
2017
11
Dengue Hemorrhagic Fever in the Northwest of Mexico: A Two-Decade Analysis. ( 28613285 )
2017
12
Spontaneous rectus sheath hematomas in dengue hemorrhagic fever: A case report. ( 28856103 )
2017
13
A pediatric case of imported dengue hemorrhagic fever in Japan. ( 29264075 )
2017
14
Serum cytokine/chemokine profiles in patients with dengue fever (DF) and dengue hemorrhagic fever (FHD) by using protein array. ( 28242509 )
2017
15
Differences in Mortality and Clinical Manifestations of Dengue Hemorrhagic Fever in Taiwan in Different Years: A Comparison for Cases in 2014 and 2015 Epidemics. ( 28722609 )
2017
16
A Correlation of the Platelet Count with D-Dimer Levels as an Indicator for Component Therapy in Children with Dengue Hemorrhagic Fever. ( 28596655 )
2017
17
Dengue Hemorrhagic Fever: A State-of-the-Art Review Focused in Pulmonary Involvement. ( 28612239 )
2017
18
Chymase Level Is a Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients. ( 28968807 )
2017
19
Management dilemmas in a rare case of pituitary apoplexy in the setting of dengue hemorrhagic fever. ( 28217383 )
2017
20
Dengue Hemorrhagic Fever: ARare Cause of Acute Liver Failure. ( 28903847 )
2017
21
IL-10 and socs3 Are Predictive Biomarkers of Dengue Hemorrhagic Fever. ( 28827898 )
2017
22
Dengue hemorrhagic fever complicated with acute liver failure: a case report. ( 29216924 )
2017
23
Corrigendum to "Does Comorbidity Increase the Risk of Dengue Hemorrhagic Fever and Dengue Shock Syndrome?" ( 29360109 )
2017
24
Management of severe dengue hemorrhagic fever and bleeding complications in a primigravidaA patient: a case report. ( 27998318 )
2016
25
Interleukin-10 as a Marker of Disease Progression in Dengue Hemorrhagic Fever. ( 26975948 )
2016
26
Dengue Hemorrhagic Fever in a Child With Early-Onset Fistulizing Crohn Disease Under Infliximab and Azathioprine Treatment. ( 26709910 )
2016
27
Complete Heart Block in Association with Dengue Hemorrhagic Fever. ( 27826348 )
2016
28
Life-Threatening Thrombo-embolic Events in a Case of Dengue Hemorrhagic Fever. ( 27762119 )
2016
29
Characterization of dengue virus infections in a sample of patients suggests unique clinical, immunological, and virological profiles that impact on the diagnosis of dengue and dengue hemorrhagic fever. ( 26990973 )
2016
30
50 Years Ago in TheJournal ofPediatrics: Shock Associated with Dengue Infection: I. Clinical and Physiological Manifestations of Dengue Hemorrhagic Fever in Thailand, 1964. ( 26922761 )
2016
31
Immature Platelet Fraction, A Simple and Useful Novel Marker in Dengue Hemorrhagic Fever. ( 26897161 )
2016
32
Acute pancreatitis complicating dengue hemorrhagic fever. ( 27812667 )
2016
33
Caveolae-mediated albumin transcytosis is enhanced in dengue-infected human endothelial cells: A model of vascular leakage in dengue hemorrhagic fever. ( 27546060 )
2016
34
Characteristics and Risk Factors for Fatality in Patients with Dengue Hemorrhagic Fever, Taiwan, 2014. ( 27273649 )
2016
35
Progress towards understanding the pathogenesis of dengue hemorrhagic fever. ( 27853992 )
2016
36
Association of BAK1 single nucleotide polymorphism with a risk for dengue hemorrhagic fever. ( 27401010 )
2016
37
Effectiveness of Recombinant Activated Factor VII (rFVII a) for Controlling Intractable Postpartum Bleeding in a case of Dengue Hemorrhagic Fever. ( 27298530 )
2016
38
Dengue hemorrhagic fever and the kidney. ( 26699788 )
2016
39
A favorable outcome from dengue hemorrhagic fever: Teaching Hospital Kandy, Sri Lanka, May 2016. ( 27652805 )
2016
40
A favorable outcome from dengue hemorrhagic fever: Teaching Hospital Kandy, Sri Lanka, May 2016. ( 28156903 )
2016
41
Human kidney damage in fatal dengue hemorrhagic fever results of glomeruli injury mainly induced by IL17. ( 26741825 )
2016
42
Vascular leakage in dengue hemorrhagic Fever is associated with dengue infected monocytes, monocyte activation/exhaustion, and cytokines production. ( 25722892 )
2015
43
Dengue hemorrhagic fever with discolored leg syndrome in a neonate: authors' reply. ( 25416092 )
2015
44
Association Between Increased Vascular Nitric Oxide Bioavailability and Progression to Dengue Hemorrhagic Fever in Adults. ( 25732810 )
2015
45
DENGUE FEVER AND DENGUE HEMORRHAGIC FEVER IN ADULTS. ( 26506734 )
2015
46
Association of combinations of interleukin-10 and pro-inflammatory cytokine gene polymorphisms with dengue hemorrhagic fever. ( 25890879 )
2015
47
Dengue Hemorrhagic Fever at 60 Years: Early Evolution of Concepts of Causation and Treatment. ( 26085471 )
2015
48
Frosted Branch Angiitis in a Patient Coinfected With Dengue Hemorrhagic Fever and Malaria. ( 26067694 )
2015
49
Dengue Hemorrhagic Fever Complicated by Intercostal Artery Hemorrhage. ( 26522190 )
2015
50
Clinico-laboratory spectrum of dengue viral infection and risk factors associated with dengue hemorrhagic fever: a retrospective study. ( 26423145 )
2015

Variations for Dengue Hemorrhagic Fever

Expression for Dengue Hemorrhagic Fever

LifeMap Discovery
Genes differentially expressed in tissues of Dengue Hemorrhagic Fever patients vs. healthy controls: 35 (show top 50) (show all 120)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CD38 CD38 molecule Blood + 4.80 0.000
2 IFI27 interferon, alpha-inducible protein 27 Blood + 4.71 0.000
3 RRM2 ribonucleotide reductase M2 Blood + 4.63 0.000
4 IGHM immunoglobulin heavy constant mu Blood + 4.61 0.000
5 BIRC5 baculoviral IAP repeat containing 5 Blood + 4.47 0.000
6 CAV1 caveolin 1, caveolae protein, 22kDa Blood + 4.41 0.000
7 DLGAP5 discs, large (Drosophila) homolog-associated protein 5 Blood + 4.31 0.000
8 XIST X inactive specific transcript (non-protein coding) Blood - 4.31 0.023
9 CEP55 centrosomal protein 55kDa Blood + 4.28 0.000
10 BUB1 BUB1 mitotic checkpoint serine/threonine kinase Blood + 4.21 0.000
11 SHCBP1 SHC SH2-domain binding protein 1 Blood + 4.13 0.000
12 PBK PDZ binding kinase Blood + 4.13 0.000
13 IGKV3-20 immunoglobulin kappa variable 3-20 Blood + 4.13 0.000
14 TYMS thymidylate synthetase Blood + 4.07 0.000
15 CDCA2 cell division cycle associated 2 Blood + 4.06 0.000
16 MKI67 marker of proliferation Ki-67 Blood + 4.00 0.000
17 CYAT1 immunoglobulin lambda light chain-like Blood + 3.98 0.000
18 MCM10 minichromosome maintenance 10 replication initiation factor Blood + 3.98 0.000
19 NOV nephroblastoma overexpressed Blood - 3.97 0.000
20 ZWINT ZW10 interacting kinetochore protein Blood + 3.96 0.000
21 CDK1 cyclin-dependent kinase 1 Blood + 3.92 0.000
22 HMMR hyaluronan-mediated motility receptor (RHAMM) Blood + 3.90 0.000
23 SDC1 syndecan 1 Blood + 3.89 0.000
24 SPC25 SPC25, NDC80 kinetochore complex component Blood + 3.84 0.000
25 NCAPG non-SMC condensin I complex, subunit G Blood + 3.84 0.000
26 TK1 thymidine kinase 1, soluble Blood + 3.82 0.000
27 CDC20 cell division cycle 20 Blood + 3.80 0.000
28 TNFRSF17 tumor necrosis factor receptor superfamily, member 17 Blood + 3.80 0.000
29 DTL denticleless E3 ubiquitin protein ligase homolog (Drosophila) Blood + 3.80 0.000
30 TOP2A topoisomerase (DNA) II alpha Blood + 3.80 0.000
31 PI3 peptidase inhibitor 3, skin-derived Blood - 3.76 0.000
32 GLDC glycine dehydrogenase (decarboxylating) Blood + 3.75 0.000
33 IGLJ3 immunoglobulin lambda joining 3 Blood + 3.75 0.000
34 SESN3 sestrin 3 Blood - 3.75 0.000
35 KIF2C kinesin family member 2C Blood + 3.74 0.000
36 CDT1 chromatin licensing and DNA replication factor 1 Blood + 3.72 0.000
37 CDKN3 cyclin-dependent kinase inhibitor 3 Blood + 3.71 0.000
38 KIAA0101 KIAA0101 Blood + 3.71 0.000
39 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Blood + 3.71 0.034
40 CNTNAP3 contactin associated protein-like 3 Blood - 3.70 0.000
41 CENPA centromere protein A Blood + 3.69 0.000
42 TTK TTK protein kinase Blood + 3.67 0.000
43 ASPM abnormal spindle microtubule assembly Blood + 3.66 0.000
44 KIF11 kinesin family member 11 Blood + 3.64 0.000
45 IGL immunoglobulin lambda locus Blood + 3.64 0.000
46 CCNB2 cyclin B2 Blood + 3.61 0.000
47 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Blood + 3.60 0.000
48 CDC6 cell division cycle 6 Blood + 3.60 0.000
49 SLC2A5 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 Blood + 3.60 0.000
50 DUSP5 dual specificity phosphatase 5 Blood + 3.60 0.000
Search GEO for disease gene expression data for Dengue Hemorrhagic Fever.

Pathways for Dengue Hemorrhagic Fever

Pathways related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 CD209 CD40LG CXCL8 FCGR2A HLA-A HLA-DRB1
2
Show member pathways
13.52 CXCL8 F2 IFNG IL10 IL6 STAT1
3
Show member pathways
13.42 CD40LG CXCL8 IL10 IL6 STAT1 STAT2
4
Show member pathways
13.29 CD40LG CXCL8 HLA-A HLA-DRB1 IFNG IL10
5
Show member pathways
13.05 CXCL8 IFNG IL10 IL6 STAT1 STAT2
6
Show member pathways
12.97 HLA-A IL6 STAT1 STAT2 TNF
7 12.85 CXCL8 IFNG IL6 STAT1 STAT2
8
Show member pathways
12.8 CD40LG CXCL8 HLA-A HLA-DRB1 IFNG IL10
9
Show member pathways
12.64 F2 IFNG IL10 IL6 STAT1 TNF
10
Show member pathways
12.62 CXCL8 HLA-A IL6 STAT1 STAT2 TNF
11 12.61 CD40LG IFNG IL10 STAT1 STAT2 TNF
12
Show member pathways
12.58 HLA-A HLA-DRB1 IFNG STAT1 STAT2
13
Show member pathways
12.5 CD209 CXCL8 HLA-A HLA-DRB1 IFNG IL6
14
Show member pathways
12.48 CD40LG IFNG IL10 IL6 TNF
15
Show member pathways
12.48 HLA-DRB1 IFNG IL10 IL6 STAT1 TNF
16 12.45 HLA-A HLA-DRB1 IL6 TNF
17
Show member pathways
12.45 CXCL8 HLA-A IFNG IL10 IL6 STAT1
18
Show member pathways
12.4 ALB F2 IFNG IL6 TNF
19
Show member pathways
12.36 CXCL8 IFNG IL6 TNF
20
Show member pathways
12.34 IFNG IL6 STAT1 STAT2
21 12.33 HLA-A HLA-DRB1 IFNG IL10
22
Show member pathways
12.33 CXCL8 IFNG IL6 STAT1 TNF
23
Show member pathways
12.29 CXCL8 F3 IL6 STAT1 TNF
24
Show member pathways
12.28 IFNG IL10 IL6 STAT1 STAT2 TNF
25
Show member pathways
12.25 IFNG STAT1 STAT2 TNF
26
Show member pathways
12.25 CXCL8 IFNG IL6 STAT1 TNF
27 12.23 IFNG IL6 STAT1 TNF
28 12.22 CXCL8 IL10 IL6 TNF
29
Show member pathways
12.21 CD209 IL10 IL6 STAT1 STAT2 TNF
30 12.19 CD209 FCGR2A HLA-A HLA-DRB1
31
Show member pathways
12.18 CD40LG FCGR2A HLA-DRB1 IFNG IL10 STAT1
32
Show member pathways
12.14 CXCL8 IFNG IL10 IL6 STAT1 STAT2
33 12.12 IL6 STAT1 STAT2 TNF
34 12.11 CXCL8 STAT1 STAT2 TNF
35 12.1 FCGR2A IFNG STAT1 STAT2 TNF
36 12.07 CXCL8 FCGR2A IFNG IL6 TNF
37
Show member pathways
12.04 HLA-A HLA-DRB1 IFNG STAT1
38 12.03 CXCL8 IL10 IL6 STAT1 TNF
39 11.97 CD209 FCGR2A IFNG IL10 IL6 TNF
40 11.95 CXCL8 IFNG IL6
41 11.95 IFNG IL10 IL6 STAT1 STAT2
42 11.95 CXCL8 F3 IL6 STAT1 TNF
43 11.93 CXCL8 IFNG IL10 IL6 TNF
44 11.91 HLA-DRB1 IL6 TNF
45 11.9 CD40LG CXCL8 TNF
46 11.89 CXCL8 HLA-DRB1 IFNG IL6 TNF
47 11.88 CXCL8 IFNG IL6 STAT1
48 11.85 CXCL8 IFNG IL6
49
Show member pathways
11.84 CD40LG CXCL8 IFNG TNF
50 11.84 CXCL8 IL10 IL6 TNF

GO Terms for Dengue Hemorrhagic Fever

Cellular components related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.73 CD209 CD40LG F3 HLA-A HLA-DRB1 TNF
2 extracellular space GO:0005615 9.65 ALB CD40LG CMA1 CXCL8 F2 F3
3 external side of plasma membrane GO:0009897 9.55 CD209 CD40LG F2 HLA-DRB1 TNF
4 extracellular region GO:0005576 9.36 ALB CD209 CD40LG CMA1 CXCL8 F2

Biological processes related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.92 CD209 HLA-A HLA-DRB1 STAT1 STAT2
2 inflammatory response GO:0006954 9.88 CD40LG CXCL8 IL10 IL6 TNF
3 positive regulation of DNA binding transcription factor activity GO:0051091 9.81 IL10 IL6 TNF
4 defense response to virus GO:0051607 9.81 IFNG IL6 STAT1 STAT2
5 type I interferon signaling pathway GO:0060337 9.76 HLA-A STAT1 STAT2
6 response to glucocorticoid GO:0051384 9.75 IL10 IL6 TNF
7 positive regulation of T cell proliferation GO:0042102 9.74 CD209 CD40LG IL6
8 humoral immune response GO:0006959 9.73 IFNG IL6 TNF
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.71 IL6 STAT1 TNF
10 regulation of signaling receptor activity GO:0010469 9.7 CD40LG CXCL8 F2 IFNG IL10 IL6
11 cellular response to lipopolysaccharide GO:0071222 9.67 CXCL8 IL10 IL6 TNF
12 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 IFNG TNF
13 interleukin-6-mediated signaling pathway GO:0070102 9.63 IL6 STAT1
14 antigen processing and presentation GO:0019882 9.63 CD209 HLA-A HLA-DRB1
15 negative regulation of growth of symbiont in host GO:0044130 9.62 IL10 TNF
16 response to molecule of bacterial origin GO:0002237 9.62 CXCL8 IL10
17 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.61 IFNG STAT1
18 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 IL10 TNF
19 negative regulation of lipid storage GO:0010888 9.6 IL6 TNF
20 endothelial cell apoptotic process GO:0072577 9.59 IL10 TNF
21 interferon-gamma-mediated signaling pathway GO:0060333 9.56 HLA-A HLA-DRB1 IFNG STAT1
22 negative regulation of cytokine secretion involved in immune response GO:0002740 9.55 IL10 TNF
23 cytokine-mediated signaling pathway GO:0019221 9.5 CXCL8 F3 IL10 IL6 STAT1 STAT2
24 regulation of immunoglobulin secretion GO:0051023 9.49 CD40LG TNF
25 receptor biosynthetic process GO:0032800 9.43 IL10 TNF
26 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.4 IFNG TNF
27 positive regulation of vitamin D biosynthetic process GO:0060557 9.32 IFNG TNF
28 immune response GO:0006955 9.28 CD40LG CMA1 CXCL8 HLA-A HLA-DRB1 IFNG

Molecular functions related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.33 CD209 HLA-A HLA-DRB1
2 tumor necrosis factor receptor binding GO:0005164 9.13 CD40LG STAT1 TNF
3 cytokine activity GO:0005125 9.1 CD40LG CXCL8 IFNG IL10 IL6 TNF
4 protein binding GO:0005515 10.13 ALB CD209 CD40LG CXCL8 F2 F3

Sources for Dengue Hemorrhagic Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....